A Phase 3 interventional study of REGN3918 in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Terminated at 14 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-12.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2019, is one of 5 in phase 3, and was the 2nd registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Italy and 4 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, Korea, Republic of, United Kingdom
Ages 18+
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Colombia and 18 more countries
Ages 18+
By country, each count listing its studies:
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5
First in 2019; this study’s year is marked. 2 started in 2019.
This study's enrollment of 24 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 24 across the 9 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the long-term safety, tolerability, and effect on intravascular hemolysis of REGN3918 in patients with paroxysmal nocturnal hemoglobinuria (PNH).
The secondary objectives of the study are:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined exclusion criteria apply
Participants who have completed 1 of the 2 parent studies (R3918-PNH-1852 \[NCT03946748\] or R3918-PNH-1853)
Drug: REGN3918
Subcutaneous (SC) every week (QW) over the treatment period
Also known as: Pozelimab
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as AEs that developed or worsened during the on-treatment period. SAE was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to Week 104
Percentage of Participants Who Achieved Lactate Dehydrogenase (LDH) Less Than or Equal to (≤) 1.5* ULN From Baseline to Week 26
Percentage of participants who achieved LDH ≤1.5\* Upper limit of normal (ULN) over Week 26, defined as LDH ≤1.5\*ULN from baseline up to Week 26 were reported. A participant was considered to have met the criteria for adequate control of intravascular hemolysis if all of their LDH readings from the baseline through Week 26 inclusive or through the analysis end date, whichever is earlier, had values ≤ 1.5\*ULN.
Time frame: Baseline up to Week 26
Percentage of Participants Who Had Breakthrough Hemolysis Through Week 26 and 78
A participant was considered to have breakthrough hemolysis if he/she had any LDH measurement greater than or equal to (≥) 2\*ULN, concomitant with associated signs or symptoms at any time subsequent to an initial achievement of disease control (i.e., LDH ≤ 1.5\* ULN).
Time frame: At Week 26 and 78
Overall Rate of Transfusion With Red Blood Cell (RBCs) Through Week 26
The overall rate of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.
Time frame: Baseline up to Week 26
Percentage of Participants Who Are Transfusion-free (With RBCs) Through Week 26 and 78
Transfusion free was defined as not having received an RBC transfusion during the first 26 and 78 weeks. A transfusion was counted only if it was per-protocol, that is, if it follows the predefined transfusion algorithm: RBC transfusion due to a post-baseline hemoglobin level less than (\<) 9 gram per deciliter (g/dL) (with anemia symptoms) or a post-baseline hemoglobin level \< 7 g/dL (without anemia symptoms).
Time frame: At Week 26 and 78
Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis Through Week 78
A participant was considered to have met the criteria for adequate control of intravascular hemolysis if all of his/her LDH readings from the baseline through Week 78 inclusive or through the analysis end date, whichever is earlier, had values \<=1.5\* ULN. and must not have discontinued study treatment early.
Time frame: Baseline up to Week 78
Percentage of Participants Who Achieved Normalization of Intravascular Hemolysis Through Week 26 and Week 78
A participant was considered to have met normalization of intravascular hemolysis if all of their LDH readings from the baseline through Week 26 or 78 inclusive, or through the analysis end date, whichever is earlier, had values ≤ 1.0\*ULN.
Time frame: Baseline, Week 26 and 78
Changes From Baseline in LDH Levels at Week 26, 78, and 104
Change from baseline in LDH levels at Week 26, 78, and 104 was reported. Reported baseline is from R3918-PNH-1852 study.
Time frame: Baseline, Week 26, 78, and 104
Percent Change From Baseline in LDH Levels at Week 26, 78, and 104
Percent change from baseline in LDH levels at Week 26, 78, and 104 was reported. Reported baseline is from R3918-PNH-1852 study.
Time frame: Baseline, Week 26, 78, and 104
Change From Baseline in Red Blood Cell (RBC) Hemoglobin Levels at Week 26, 78, and 104
Change from baseline in RBC hemoglobin levels at Week 26, 78, and 104 was reported.
Time frame: Baseline, Week 26, 78, and 104
Change From Baseline in Free Hemoglobin Levels at Week 26, 78 and 104
Change from baseline in free hemoglobin levels at Week 26, 78 and 104 was reported.
Time frame: Baseline, Week 26, 78 and 104
Serum Concentrations of Total REGN3918
Serum Concentrations of total REGN3918 was reported.
Time frame: Pre-dose (Day 1), End of infusion at Week 13, 26, 39, 52, 65, 78, 91 and 104
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) to REGN3918
Number of Participants with treatment-emergent ADA response to REGN3918 was reported. The ADA analysis set (AAS) includes all treated participants who received any amount of study drug (active \[SAF\]) and had at least 1 non missing anti pozelimab antibody result following the first dose of study drug. The AAS is based on the actual treatment received (as treated).
Time frame: Baseline up to Week 104
| Milestone | REGN3918 |
|---|---|
| Started | 24 |
| Completed | 0 |
| Not completed | 24 |
| Withdrew: Withdrawn due to sponsor's decision | 24 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as AEs that developed or worsened during the on-treatment period. SAE was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | REGN3918 |
|---|---|
| Participants with TEAEs | 15 |
| Participants with Serious TEAEs | 2 |
Percentage of participants who achieved LDH ≤1.5\* Upper limit of normal (ULN) over Week 26, defined as LDH ≤1.5\*ULN from baseline up to Week 26 were reported. A participant was considered to have met the criteria for adequate control of intravascular hemolysis if all of their LDH readings from the baseline through Week 26 inclusive or through the analysis end date, whichever is earlier, had values ≤ 1.5\*ULN.
| Percentage of participants | REGN3918 |
|---|---|
| Percentage of Participants Who Achieved Lactate Dehydrogenase (LDH) Less Than or Equal to (≤) 1.5* ULN From Baseline to Week 26 | 95.7 (87.3 to 100.0) |
A participant was considered to have breakthrough hemolysis if he/she had any LDH measurement greater than or equal to (≥) 2\*ULN, concomitant with associated signs or symptoms at any time subsequent to an initial achievement of disease control (i.e., LDH ≤ 1.5\* ULN).
| Percentage of participants | REGN3918 |
|---|---|
| At Week 26 | 0 (0 to 0) |
| At Week 78 | 0 (0 to 0) |
The overall rate of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.
| Transfusion per person-year of treatment | REGN3918 |
|---|---|
| Overall Rate of Transfusion With Red Blood Cell (RBCs) Through Week 26 | 0.164 (0.006 to 4.678) |
Transfusion free was defined as not having received an RBC transfusion during the first 26 and 78 weeks. A transfusion was counted only if it was per-protocol, that is, if it follows the predefined transfusion algorithm: RBC transfusion due to a post-baseline hemoglobin level less than (\<) 9 gram per deciliter (g/dL) (with anemia symptoms) or a post-baseline hemoglobin level \< 7 g/dL (without anemia symptoms).
| Percentage of participants | REGN3918 |
|---|---|
| At Week 26 | 95.7 (87.3 to 100.0) |
| At Week 78 | 93.8 (81.9 to 100.0) |
A participant was considered to have met the criteria for adequate control of intravascular hemolysis if all of his/her LDH readings from the baseline through Week 78 inclusive or through the analysis end date, whichever is earlier, had values \<=1.5\* ULN. and must not have discontinued study treatment early.
| Percentage of participants | REGN3918 |
|---|---|
| Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis Through Week 78 | 93.8 (81.9 to 100.0) |
A participant was considered to have met normalization of intravascular hemolysis if all of their LDH readings from the baseline through Week 26 or 78 inclusive, or through the analysis end date, whichever is earlier, had values ≤ 1.0\*ULN.
| Percentage of participants | REGN3918 |
|---|---|
| At Week 26 | 75.0 (57.7 to 92.3) |
| At Week 78 | 55.0 (33.2 to 76.8) |
Change from baseline in LDH levels at Week 26, 78, and 104 was reported. Reported baseline is from R3918-PNH-1852 study.
| Units per liter (U/L) | REGN3918 |
|---|---|
| At Week 26 | -5.098 ± 2.5695 |
| At Week 78 | -5.395 ± 2.8468 |
| At Week 104 | -5.270 ± 2.9057 |
Percent change from baseline in LDH levels at Week 26, 78, and 104 was reported. Reported baseline is from R3918-PNH-1852 study.
| Percent change | REGN3918 |
|---|---|
| At Week 26 | -81.900 ± 8.9226 |
| At Week 78 | -84.256 ± 8.1412 |
| At Week 104 | -83.930 ± 7.6705 |
Change from baseline in RBC hemoglobin levels at Week 26, 78, and 104 was reported.
| Gram per liter (g/l) | REGN3918 |
|---|---|
| At Week 26 | 3.6 ± 8.97 |
| At Week 78 | 5.3 ± 17.20 |
| At Week 104 | -2.4 ± 16.56 |
Change from baseline in free hemoglobin levels at Week 26, 78 and 104 was reported.
| Milligram per deciliter (mg/dL) | REGN3918 |
|---|---|
| At Week 26 | -1.39 ± 6.929 |
| At Week 78 | -0.56 ± 2.196 |
| At Week 104 | -0.93 ± 1.153 |
Serum Concentrations of total REGN3918 was reported.
| Milligrams per liter (mg/L) | REGN3918 |
|---|---|
| Pre-dose (Day 1) | 423 ± 218 |
| Week 13 | 398 ± 203 |
| Week 26 | 401 ± 212 |
| Week 39 | 420 ± 216 |
| Week 52 | 413 ± 202 |
| Week 65 | 438 ± 207 |
| Week 78 | 433 ± 266 |
| Week 91 | 483 ± 278 |
Number of Participants with treatment-emergent ADA response to REGN3918 was reported. The ADA analysis set (AAS) includes all treated participants who received any amount of study drug (active \[SAF\]) and had at least 1 non missing anti pozelimab antibody result following the first dose of study drug. The AAS is based on the actual treatment received (as treated).
| Participants | REGN3918 |
|---|---|
| Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) to REGN3918 | 0 |
Collected over From first dose to Week 104. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| REGN3918 | 0/24 (0%) | 2/24 (8.3%) | 6/24 (25%) |
| Event | REGN3918 |
|---|---|
| Abdominal painGastrointestinal disorders | 1/24 |
| InfluenzaInfections and infestations | 1/24 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/24 |
| Event | REGN3918 |
|---|---|
| Mouth ulcerationGastrointestinal disorders | 2/24 |
| ChillsGeneral disorders | 2/24 |
| HeadacheNervous system disorders | 2/24 |
| RashSkin and subcutaneous tissue disorders | 2/24 |
Safety Analysis Set (SAF) included all enrolled participants who received any study drug.
| Age, Continuous(Years) | REGN3918 |
|---|---|
| Mean | 45.8 ± 17.26 |
| Sex: Female, Male(Participants) | REGN3918 |
|---|---|
| Female | 11 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | REGN3918 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | REGN3918 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 21 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Dec 2019 to primary completion in Apr 2022, 28 months.
Results were first posted in Jun 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pozelimab